Please login to the form below

siponimod

This page shows the latest siponimod news and features for those working in and with pharma, biotech and healthcare.

Novartis’ MS therapy Mayzent approved by NICE

Mayzent (siponimod), a sphinogosine 1-phosphate receptor modulator, is the first oral disease-modifying treatment recommended by both NICE and the Scottish Medicines Consortium (SMC) for SPMS with active disease.

Latest news

Novartis wins FDA approval for relapsing MS drug Kesimpta

Kesimpta’s approval in relapsing MS builds on Novartis’ existing presence in the therapy area, which includes its active secondary progressive multiple sclerosis (SPMS) therapy Mayzent (siponimod).
Novartis builds its case for novel MS treatment ofatumumab

The drug is an important product in Novartis’ growing MS franchise, which currently includes Mayzent (siponimod), a next-generation treatment approved for use in active secondary progressive multiple sclerosis (SPMS).
J&J aims for US approval of MS drug ponesimod

If approved, ponesimod will compete directly with Novartis’ S1P receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod), which is approved for secondary progressive forms of MS only
Cosentyx, Entresto drive topline growth for Novartis in Q4

Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer treatment Piqray (alpelisib), multiple sclerosis drug Mayzent (siponimod), wet age-related macular degeneration treatment Beovu (brolucizumab) and
Novartis gets EU approval for multiple sclerosis therapy Mayzent

Offers subgroup of patients an important new treatment option. The European Commission has approved Novartis’ Mayzent (siponimod) for use in adults with active secondary progressive multiple sclerosis (SPMS).

More from news
Approximately 2 fully matching, plus 14 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow
Tackling a formidable foe

Novartis has announced positive phase III trial data for siponimod, a drug for secondary progressive MS, which reduced the risk of a patient’s disability worsening by 21% after three months

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Medical Editor: Competitive

Account Director – Creative Healthcare Communications: Competative

Healthcare Lead Copywriter: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Healthcare Senior Account Manager: Competitive

Healthcare Account Director: Competitive

PMHub

Add my company

Jet Off with Maloff Protect

Latest intelligence

The pandemic preparedness paradox: Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Sourcing R&D innovation: why pharma companies need to evolve their business models: Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?: 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...